These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
401 related items for PubMed ID: 10555385
41. [Conservative therapy of inflammatory bowel diseases]. Nagy F. Orv Hetil; 2002 Dec 15; 143(50):2763-8. PubMed ID: 12583315 [Abstract] [Full Text] [Related]
42. [Biological therapy as treatment of inflammatory bowel diseases]. Agnholt J. Ugeskr Laeger; 2008 Jun 09; 170(24):2152-6. PubMed ID: 18565302 [Abstract] [Full Text] [Related]
43. Inflammatory Bowel Disease - Non-biological treatment. Magro F, Cordeiro G, Dias AM, Estevinho MM. Pharmacol Res; 2020 Oct 09; 160():105075. PubMed ID: 32653651 [Abstract] [Full Text] [Related]
44. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies. de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. Am J Gastroenterol; 2016 Sep 09; 111(9):1305-12. PubMed ID: 27349339 [Abstract] [Full Text] [Related]
45. Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients. Krajcovicova A, Hlavaty T, Killinger Z, Miznerova E, Toth J, Letkovsky J, Nevidanska M, Cierny D, Koller T, Zelinkova Z, Huorka M, Payer J. J Crohns Colitis; 2014 Dec 09; 8(12):1693-701. PubMed ID: 25175812 [Abstract] [Full Text] [Related]
46. Medical therapies for inflammatory bowel disease. Stotland BR, Cirigliano MD, Lichtenstein GR. Hosp Pract (1995); 1998 May 15; 33(5):141-4, 149-51, 156 passim. PubMed ID: 9606359 [Abstract] [Full Text] [Related]
47. Infliximab for postsurgical endoscopic recurrence of Crohn's disease: no trumpets yet. Sorrentino D, Paviotti A. Inflamm Bowel Dis; 2009 Oct 15; 15(10):1458-9. PubMed ID: 19462431 [No Abstract] [Full Text] [Related]
48. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, Dignass A, Hartmann F, Zeuzem S, Stein J, Schröder O. J Crohns Colitis; 2011 Jun 15; 5(3):203-10. PubMed ID: 21575882 [Abstract] [Full Text] [Related]
49. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, Vedrines P, Duru G, Peyrin-Biroulet L, Nancey S, Flourie B, Paul S. Gut; 2020 Jul 15; 69(7):1206-1212. PubMed ID: 31980448 [Abstract] [Full Text] [Related]
53. Transcending conventional therapies: the role of biologic and other novel therapies. Sandborn WJ. Inflamm Bowel Dis; 2001 May 15; 7 Suppl 1():S9-16. PubMed ID: 11380043 [Abstract] [Full Text] [Related]
54. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis. Calderón R, Estrada S, Ramírez de la Piscina P, Salvador M, Zabaleta S, Enciso C, Delgado E, García-Campos F. Rev Esp Enferm Dig; 2010 Feb 15; 102(2):145-6. PubMed ID: 20361852 [No Abstract] [Full Text] [Related]
55. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Peyrin-Biroulet L. Minerva Gastroenterol Dietol; 2010 Jun 15; 56(2):233-43. PubMed ID: 20485259 [Abstract] [Full Text] [Related]